KPT-276
Based on 1 Customer Validation
KPT-276 is an orally active and blood-brain barrier-penetrant selective XPO1/CRM1 inhibitor. KPT-276 blocks XPO1-mediated nuclear export function and promotes nuclear retention of various tumor suppressor proteins. KPT-276 induces apoptosis and G1 cell cycle arrest in tumor cells, and downregulates c-MYC, CDC25A, and BRD4. KPT-276 reduces immune cell proliferation through nuclear accumulation of cell cycle inhibitors, rescues TDP-43 cytoplasmic mislocalization, and restores axon growth and growth rate in mutant PFN1 motor neurons. KPT-276 maintains axonal cytoskeletal integrity and mitochondrial function, and inhibits tumor growth. KPT-276 can be used for research on glioblastoma, non-Hodgkin lymphoma, amyotrophic lateral sclerosis, multiple myeloma, and non-small cell lung cancer.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 1421919-75-6
- Formula: C16H10F8N4O
- Molecular Weight:426.26
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Biological Activity
Description
|
BRD4 |
IL-10 |
IL-17A |
IL-6 |
TNF-α |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| U-266 | IC50 |
488 nM
|
Antiproliferative activity against human U266 myeloma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human U266 myeloma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
23752175 |
| RPMI-8226 | IC50 |
903 nM
|
Antiproliferative activity against human RPMI-8226 myeloma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human RPMI-8226 myeloma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
23752175 |
In Vitro
KPT-276 (100 nM - 10 mM; 5 days) inhibits the growth of primary human adult and pediatric GBM cell lines (BT 145, BT 159, BT 172, AGBM1, BT 245, DIPG 4, DIPG 6) under neurosphere culture conditions with submicromolar IC50 values[1].
KPT-276 (IC50, 2 x IC90; 48 h) causes a dose-dependent decrease in MCL1 protein levels in AGBM1 cells, but this effect is not observed in BT 145 or BT 159 cells, indicating that MCL1 reduction is not a universal mechanism of increased apoptosis in GBM cells[1].
KPT-276 (15.625-1000 nM; 72 h) reduces the viability of 12 human myeloma cell lines with a median IC50 of approximately 160 nM[5].
KPT-276 (15.6-1000 nM; 72 h) exhibits synergy with the BRD4 inhibitor JQ1 in the resistant HMCLs RPMI-8226, U266, and KMS18[5].
KPT-276 (50 nM) treatment of mouse primary motor neurons expressing mutant PFN1C71G rescues TDP-43 mislocalization; rescues axonal growth defects; rescues axonal growth rate defects[4].
KPT-276 (IC80 dose; 6-48 h) leads to differential expression of genes in sensitive HMCLs MM1.S and OCI-MY5, including downregulation of CDC25A and BRD4; it reduces c-Myc, CDC25A, and BRD4 protein levels in MM1.S and OCI-MY5 cells[5].
KPT-276 disrupts the binding of CRM1 to PKI NES in vitro[6].
KPT-276 (0.1-1,000 nM; 24 h) exhibits low cytotoxicity in cultured spinal cord neurons, cortical neurons, mature oligodendrocytes, and splenocytes[6].
KPT-276 (24 h) induces G1 phase cell cycle arrest and reduces the S phase cell population in MM1.S cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BT 145, BT 159, BT 172, AGBM1, BT 245, DIPG 4, DIPG 6
-
Concentration:100 nM - 10 mM
-
Incubation Time:5 days
-
Result:Inhibited growth with a combined IC50 range of 6-354 nM for the three SINE compounds tested in parallel.
-
Cell Line:mouse primary motor neurons expressing V5-tagged PFN1C71G or PFN1WT
-
Concentration:50 nM
-
Incubation Time:6 h
-
Result:Fully rescued TDP-43 cytoplasmic mislocalization in MNs expressing PFN1C71G.
-
Cell Line:mouse primary motor neurons expressing V5-tagged PFN1C71G or PFN1WT
-
Concentration:50 nM
-
Incubation Time:3 days
-
Result:Fully rescued the axon length defect in MNs expressing PFN1C71G.
-
Cell Line:KMS11, KMS12PE, KMS18, OPM2, H929, JJN3, U266, 8226, MY5, SKMM2, MM1R and MM1S
-
Concentration:15.6, 31.3, 62.5, 125, 250, 500, 1000 nM
-
Incubation Time:72 h
-
Result:Reduced cell viability in multiple human multiple myeloma cell lines (including KMS11, KMS12PE, KMS18, OPM2, H929, JJN3, U266, 8226, MY5, SKMM2, MM1R and MM1S) in a concentration‑dependent manner.
-
Cell Line:RPMI-8226, U266, KMS18
-
Concentration:0, 15.6, 31.3, 62.5, 125, 250, 500, 1000 nM
-
Incubation Time:72 h
-
Result:Decreased viability at concentrations lower than treatment with KPT-276 alone.
Synergy observed with JQ1 in all three cell lines with combination index values of 0.258 for RPMI-8226 (KPT-276 IC50 of 903 nM), 0.335 for U266 (KPT-276 IC50 of 488 nM), and 0.063 for KMS18 (KPT-276 IC50 of 176 nM).
Parmacokinetics
| Species | Dose | Route | Brain Concentration | Plasma Concentration |
|---|---|---|---|---|
| Rat[7] | 2 mg/kg | p.o. | 70.5 ng/mL | 17.6 ng/mL |
In Vivo
KPT-276 (75-150 mg/kg; p.o.; 13 days) shows similar or stronger antitumor potential compared with CHOP in the WSU-DLCL2 mouse xenograft model[2].
KPT-276 (100 mg/kg; p.o.; three times per week; 16 days) significantly inhibits tumor growth in the Jeko-1 xenograft mouse model and is well tolerated[3].
KPT-276 (p.o.; 3 days per week; 12 days, followed by a 10-day drug holiday, then resumed dosing) reduces MM1.S xenograft tumor volume by 40% and remains active when dosing is restarted after treatment interruption[5].
KPT-276 (150 mg/kg; p.o.; 3 days/week; 3 weeks) reduces the serum M protein peak by an average of 57% in the Vk*MYC transgenic MM mouse model[5].
KPT-276 (75 mg/kg; p.o.; every other day; 12 days) treatment significantly alleviates EAE, reducing the cumulative disease score to 60% of that in the vehicle group [6].
KPT-276 (75 mg/kg; p.o.; every other day; 19 days) reduces disease onset and severity in the EAE model[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID gamma (NSG) mice (BT 145-luc cells 1.8 × 105 cells/μL in PBS)[1]
-
Dosage:50 mg/kg (escalated to 75 mg/kg after 1 week)
-
Administration:p.o.; 3 times a week (Monday, Wednesday, Friday)
-
Result:Showed reduced intracranial tumor growth assessed by BLI relative to vehicle.
Confirmed diminished tumor burden on day‑61 MRI versus vehicle‑treated controls.
Demonstrated extended animal survival compared with vehicle.
Revealed decreased proportion of MCL1‑positive tumor cells relative to vehicle‑treated controls.
Detected increased fraction of TUNEL‑positive tumor cells versus vehicle (3.2% vs 1.2%).
Found comparable tumor‑cell‑density ratios between main tumor mass and invasive regions across groups.
Observed comparable fractions of NUMA1‑positive cells co‑expressing MKI67 across groups.
-
Animal Model:NOD/SCID (male, 7-week-old, Jeko-1 cells (1 × 107 cells) were subcutaneously inoculated into the flank)[3]
-
Dosage:100 mg/kg
-
Administration:p.o.; three times a week; 16 days
-
Result:Inhibited tumor growth more significantly than vehicle control.
Caused a maximum body-weight loss of 15%.
Enhanced nuclear staining for survivin in tumor sections.
-
Animal Model:Vk*MYC transgenic mice[5]
-
Dosage:150 mg/kg (formulated in 0.6% (w/v) Pluronic F‑68 and 0.6% (w/v) PVP K‑29/32)
-
Administration:p.o.; 3 days/week; 3 weeks
-
Result:Reduced the M-spike by an average of 52% after 2 weeks.
Reduced the M-spike by an average of 57% over 3 weeks compared with day 0 levels.
-
Animal Model:C57BL/6J (female, 8 weeks old, immunized with 300 μg MOG35-55 emulsified in complete Freund’s adjuvant)[6]
-
Dosage:75 mg/kg
-
Administration:p.o. (oral gavage); every other day; 12 days
-
Result:Reduced the cumulative disease score to 60% of the vehicle group.
Preserved both myelinated and demyelinated axons in the lumbo-sacral area of the spinal cord.
Reduced the numbers of CD45+ leukocytes, B220+ B cells, and CD4+ and CD8+ T cells in the CNS.
Decreased cytokine messenger RNA levels (Il6, Tgfb1, Il10, Il17a, Tnf, Ifng).
Increased nuclear accumulation of cell cycle inhibitory molecules (e.g., p27Kip1) fourfold.
Resulted in fewer axons with Wallerian degeneration and preserved axons per unit area in the lumbosacral spinal cord.
-
Animal Model:C57BL/6J (female, 8 weeks old, immunized with 300 μg MOG35-55 emulsified in complete Freund’s adjuvant)[6]
-
Dosage:75 mg/kg
-
Administration:p.o. (oral gavage); every other day; prophylactic treatment started concurrently with immunization for 19 days
-
Result:Decreased both disease onset and severity.
Reduced B220+ B cells, and CD4+ and CD8+ T cells in the spinal cord.
Reduced the total number of splenocytes and splenic cell populations.
Chemical Information
-
CAS No. 1421919-75-6
-
Appearance Solid
-
Molecular Weight 426.26
-
Formula C16H10F8N4O
-
Color White to off-white
-
SMILES
O=C(N1CC(F)(F)C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
In Vitro:
DMSO : 20 mg/mL (46.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (4.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Phalloidin F-actin cytoskeleton staining
Phalloidin F-actin staining detects polymerized filamentous actin in fixed and permeabilized specimens by using fluorescent phalloidin or phalloidin-derived phallotoxins that bind actin filaments and generate a fluorescence microscopy readout corresponding to F-actin organization, including stress fibers, cortical actin, filament bundles, and tissue-specific actin networks. Phalloidin stabilizes F-actin by reducing actin subunit dissociation from filament ends, and fluorescent phallotoxins were established as tools for visualizing actin-containing structures in eukaryotic cells.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (302 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3460 mL | 11.7299 mL | 23.4599 mL | 58.6496 mL |
| 5 mM | 0.4692 mL | 2.3460 mL | 4.6920 mL | 11.7299 mL | |
| 10 mM | 0.2346 mL | 1.1730 mL | 2.3460 mL | 5.8650 mL | |
| 15 mM | 0.1564 mL | 0.7820 mL | 1.5640 mL | 3.9100 mL | |
| 20 mM | 0.1173 mL | 0.5865 mL | 1.1730 mL | 2.9325 mL | |
| 25 mM | 0.0938 mL | 0.4692 mL | 0.9384 mL | 2.3460 mL | |
| 30 mM | 0.0782 mL | 0.3910 mL | 0.7820 mL | 1.9550 mL | |
| 40 mM | 0.0586 mL | 0.2932 mL | 0.5865 mL | 1.4662 mL |